Views & Analysis Health literacy: help pharma communicate with patients Health literacy study suggests more than 90% of adults need health information to be written for a reading age of 9-11 years.
Views & Analysis Deep Dive: Oncology magazine launched today Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
Views & Analysis To PSP or not to PSP? That is NOT the question A practical guide to planning and running an effective patient support programme.
Views & Analysis Non-profit model for childhood cancer drugs Charities must work to help pharma and academia prioritise and accelerate paediatric treatments.
Views & Analysis Getting a rarer perspective Benefitting from insights from focus groups with rare disease patients.
Views & Analysis Patient-centricity and long-term conditions – where next? Comprehensive guidance, education and training are vital to upskill clinicians and others in patient-centred healthcare.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.